The Europe Coagulation Analyzer Market was valued at $353.4 Million in 2025 and projected to reach to $488.9 Million by 2030, representing a compound annual growth rate of 6.7%. Europe's coagulation analyzer market is positioned for steady expansion through 2030, driven by an aging population with increasing cardiovascular and thrombotic disease prevalence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's coagulation analyzer market is valued at $353.4 million in 2025 and is projected to reach $488.9 million by 2030, representing a steady CAGR of 6.7% over the forecast period.
Europe's rapidly aging demographic is significantly increasing the prevalence of thrombotic and bleeding disorders, creating sustained demand for advanced coagulation diagnostic solutions across hospitals and laboratories.
The UK leads European adoption with $292 million in market size, followed by Germany at $196.1 million, reflecting strong healthcare infrastructure and high diagnostic testing volumes in Western Europe.
Heightened awareness of bleeding and clotting complications, combined with stringent European regulatory standards, is driving adoption of sophisticated coagulation analyzers in clinical settings across the region.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ANTI-FACTOR XA TESTS (Test) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 7.2% from 2025 to 2030 |
| Largest Segment | CLINICAL LABORATORY ANALYZERS (Product) |
| Market Size Base Year (Billions) | ~USD 3.77 (2025) |
| Revenue Forecast (Billions) | ~USD 5.34 (2030) |
| Segments Covered | Product, Type, Test, Testing Site, Technology, End User, Site Of Testing |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 187.8 | 196.9 | 207.1 | 220.8 | 234.2 | 266.6 | 284.3 | 303.2 | 6.6 |
| HOSPITALS | 284.8 | 302.3 | 321.7 | 347.1 | 372.5 | 434.3 | 468.4 | 505.4 | 7.8 |
| OTHER END USERS | 93.3 | 98.4 | 104.1 | 111.6 | 119 | 137 | 146.9 | 157.6 | 7.2 |
| TOTAL | 565.9 | 597.6 | 632.9 | 679.4 | 725.7 | 838 | 899.6 | 966.2 | 7.3 |
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 48.2 | 50 | 52 | 54.9 | 57.6 | 64.1 | 67.6 | 71.3 | 5.4 |
| HOSPITALS | 74 | 77.7 | 81.8 | 87.3 | 92.7 | 105.7 | 112.8 | 120.4 | 6.6 |
| OTHER END USERS | 24.1 | 25.1 | 26.3 | 27.8 | 29.3 | 33 | 35 | 37.1 | 5.9 |
| TOTAL | 146.4 | 152.9 | 160.1 | 170 | 179.6 | 202.8 | 215.4 | 228.8 | 6.1 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SYSMEX CORPORATION | Japan | ||
| SIEMENS HEALTHINEERS AG | Germany | ||
| F. HOFFMANN-LA ROCHE LTD. | United States | ||
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Clinical Laboratory Analyzers,Consumables,Reagents, |
| NIHON KOHDEN CORPORATION | Japan | Public Company | Clinical Laboratory Analyzers,Reagents,Consumables, |
| BIOSYNEX SA | France | Public Company | Clinical Laboratory Analyzers,Consumables,Reagents, |
| ABBOTT | United States | Public Company | Clinical Laboratory Analyzers,Consumables,Reagents, |
| DANAHER | United States | Public Company | Clinical Laboratory Analyzers,Consumables,Reagents, |
| HORIBA, LTD. | Japan | Public Company | Clinical Laboratory Analyzers,Reagents,Consumables, |
| MACCURA BIOTECHNOLOGY CO., LTD. | China | Public Company | Clinical Laboratory Analyzers (Coagulation Systems),Consumables & Reagents (PT, APT, D-Dimer and related),Systems & Automation (integration, software, service), |
Sysmex Corporation is a Japanese diagnostics company manufacturing hematology, hemostasis, and urinalysis analyzers.
Siemens Healthineers AG is a German medical technology company offering diagnostic imaging, laboratory diagnostics, and point-of-care solutions.
F. Hoffmann-La Roche Ltd. is a Swiss pharmaceutical and diagnostics company developing medicines, vaccines, and in vitro diagnostic tests.
Thermo Fisher Scientific Inc. is a leading provider of laboratory equipment, reagents, and services for research, diagnostics, and bioproduction, founded in 1956 with approximately 125,000 employees.
Nihon Kohden Corporation is a Japanese medical device manufacturer specializing in patient monitoring, diagnostic imaging, and clinical laboratory equipment, founded in 1951 with 6,116 employees.
Biosynex SA is a French in vitro diagnostics company founded in 2005, publicly traded with 397 employees specializing in rapid diagnostic tests.
Abbott is a diversified U.S. healthcare company founded in 1888 with approximately 115,000 employees, providing pharmaceuticals, diagnostics, nutritional products, and medical devices.
Danaher is a U.S. conglomerate founded in 1969 with 59,000 employees operating across diagnostics, life sciences, environmental, and industrial segments.
Horiba, Ltd. is a Japanese public company founded in 1945 with 9,101 employees manufacturing analytical and measurement instruments for automotive, medical, and environmental applications.
Maccura Biotechnology Co., Ltd. is a Chinese diagnostics company founded in 1994 with 2,875 employees producing clinical laboratory analyzers and reagents.
| Country | 2025 size (native) |
|---|---|
| Germany | USD 196.1 Million |
| UK | USD 292 Million |
| France | USD 64.1 Million |
| Italy | USD 40.2 Million |
| Spain | USD 23.1 Million |
| Rest Of Europe | USD 114 Million |
Europe's coagulation analyzer market is valued at $353.4 million in 2025 and is expected to grow to $488.9 million by 2030.
Europe's coagulation analyzer market is projected to grow at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2030.
Key drivers include Europe's aging population, increasing prevalence of thrombotic and cardiovascular disorders, stringent regulatory requirements, and growing adoption of laboratory automation and point-of-care testing solutions.
Europe's largest markets include Germany, France, the United Kingdom, and Italy, where advanced healthcare infrastructure and high diagnostic spending support robust coagulation analyzer adoption.
Europe is experiencing increased adoption of automated, high-throughput analyzers, point-of-care testing devices, and integrated laboratory information systems that improve efficiency and patient outcomes.
This study extensively utilized both primary and secondary sources. Initially, secondary research methods were employed to gather data about the market, including its parent and peer markets. The next phase involved conducting primary research to validate these conclusions and assumptions by engaging with industry experts throughout the value chain. A combination of top-down and bottom-up approaches was applied to assess the overall market size. Subsequently, the market sizes of segments and subsegments were estimated using data triangulation techniques and market breakdown analysis.
The secondary research process extensively utilizes a variety of secondary sources, including directories and databases such as Bloomberg Business, Factiva, and D&B Hoovers. It incorporates white papers, annual reports, investor presentations, and SEC filings from companies, along with publications from government bodies like the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the US Census Bureau, the World Health Organization (WHO), the International Trade Administration (ITA), the International Society on Thrombosis and Haemostasis (ISTH), the European Hematology Association (EHA), and the World Federation of Hemophilia (WFH). These resources were accessed to gather and analyze information for the global coagulation analyzers market study. The research aimed to identify key players in the market, categorize and segment the information according to industry trends, and capture important developments related to the market and technology perspectives. Additionally, a database of leading industry figures was created using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. The primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from important companies and organizations in the coagulation analyzers market. On the demand side, primary sources included hospitals, clinical laboratories, and other end users. This primary research was conducted to validate market segmentation, identify key players, and collect insights on significant industry trends and market dynamics.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, CFOs, COOs, and VPs.
Note 2: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024, Tier 1= >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = < USD 1 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Annual revenues were calculated based on revenue data from major product manufacturers and OEMs involved in the global coagulation analyzers market to determine the global market value. Key manufacturers were identified at both the global and regional levels. Revenue mapping for their respective business segments and subsegments was conducted for these leading players.
The global coagulation analyzers market was categorized into various segments and subsegments based on the following criteria:
This data was consolidated, along with detailed inputs and analysis from MarketsandMarkets, and presented in this report.

After arriving at the overall size of the global coagulation analyzers market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Examining several macrovariables and regional trends from demand- and supply-side players helped triangulate the extrapolated market data.
A coagulation analyzer is an important medical diagnostic tool that checks how well blood can clot by measuring several key factors, including prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and fibrinogen levels. This device plays a crucial role in diagnosing bleeding disorders like hemophilia, monitoring anticoagulant therapies with drugs such as aspirin, heparin, or warfarin, and managing patients during surgeries. Coagulation analyzers provide fast and accurate evaluations of clotting efficiency and platelet counts, which helps healthcare providers make quick clinical decisions in both hospital and lab environments.
Full forecast, segment splits, and company analysis for all Coagulation Analyzer Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report